#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Metastases to central nervous system Short stature homeobox gene mutation Mycobacterium abscessus infection Marginal zone lymphoma refractory Fms-like tyrosine kinase 3 positive Primary biliary cholangitis Hepatobiliary cancer X-linked lymphoproliferative syndrome Endometrial cancer Chronic graft versus host disease in intestine Gaucher's disease type I Hereditary haemorrhagic telangiectasia Obesity Infection in an immunocompromised host Bronchopulmonary aspergillosis More trials…

    Learn about Rare Diseases

    Anaplastic thyroid cancer – Basic Information Hairy cell leukaemia recurrent – Basic Information Pemphigus – Life with Disease Cytokine release syndrome – Basic Information Glomerulonephritis membranoproliferative – Basic Information VEXAS syndrome – Treatment Ewing’s sarcoma recurrent – Diagnostics Nodal marginal zone B-cell lymphoma Medulloblastoma – Basic Information Crigler-Najjar syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Certolizumab Pegol Bimekizumab SALICYLIC ACID ZILUCOPLAN AZD3632 Vafidemstat Sirexatamab Tinzaparin Sodium Ilofotase Alfa Tx200-Tr101 Idelalisib Capecitabine SEPOFARSEN Imipramine Hydrochloride Fluorescein Sodium LUNSEKIMIG Boserolimab Travoprost Caspofungin Ziclumeran More therapies…

    Learn about Your Condition

    Coma Laryngeal cancer stage III Endocrine disorder Glioblastoma Malignant peritoneal neoplasm Anal fistula Renal cancer metastatic Chronic sinusitis Guttate psoriasis Hip arthroplasty Gallbladder cancer Graft versus host disease Transitional cell carcinoma Hyperparathyroidism secondary Pancreaticoduodenectomy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Klinikum Nuernberg

Klinikum Nuernberg

Prof.-Ernst-Nathan-Strasse 1, St. Johannis, Nürnberg, 90419, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Nivolumab to Placebo for Patients with High-Risk Invasive Bladder Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Nivolumab
    Austria Belgium Denmark France Germany Greece +7

  • Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Bortezomib
    • Isatuximab
    Germany

  • Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Carfilzomib
    • Dexamethasone
    • Mezigdomide
    Austria Bulgaria Denmark Germany Greece Hungary +5

  • Study of Pembrolizumab as Additional Treatment for Patients with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma After Surgery and Radiation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Squamous cell carcinoma
    Investigated Drugs:
    • Pembrolizumab
    France Germany Greece Hungary Ireland Italy +5

  • Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Enzalutamide
    • Pembrolizumab
    Austria Bulgaria Czechia France Germany Hungary +5

  • Study Comparing Docetaxel, Darolutamide, and ADT for Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Buserelin Acetate
    • Degarelix
    • Leuprorelin Acetate
    Austria Germany

  • Study of Nivolumab, Ipilimumab, or Cabazitaxel for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Cabazitaxel
    • Ipilimumab
    • Nivolumab
    Germany

  • Study on Atezolizumab and Bevacizumab for Patients with Unresectable Liver Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    Germany

  • Study on Mecasermin Rinfabate for Preventing Chronic Lung Disease in Extremely Premature Babies

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Mecasermin Rinfabate
    Finland Germany Ireland Italy The Netherlands Portugal +1

  • Study of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Disodium Folinate
    • Docetaxel
    • Fluorouracil
    Germany
Previous Page
1 … 8 9 10 11
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!